Toxicity prediction in radiotherapy for pelvic cancers, assessing the added value of biological parameters to RT treatment planning variables

Recruiting

• Conditions: pelvic cancers; pelvic tumors; 10038588

• Registration Number: NL-OMON55564
• Lead Sponsor: Academisch Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 15 April 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 200

Inclusion Criteria

-Histologically confirmed urogenital carcinoma (i.e. cervix, uterus, vagina,
vulva, prostate, bladder) or rectal cancer
-Newly diagnosed patients who are to receive 'radical' EBRT or already treated
patients, 6 to 24 months after curative EBRT. (Both patients receiving primary
RT and those receiving adjuvant (post-operative) RT are eligible for this study)
-Proficient in Dutch
-Written informed consent prior to participation

Exclusion Criteria

-Radiotherapy for recurrent disease
-Patients with prostate cancer who had prostatectomy or iodine-125
brachytherapy
-Psychosocial or somatic disorders in the medical history, limiting the
possibilities for adequate follow-up

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Late radiation toxicity</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Not applicable</p><br>